RECURRENT MANTLE CELL LYMPHOMA
Clinical trials for RECURRENT MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blood cancer patients after CAR t fails
Disease control CompletedThis study tested a drug called nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab helps the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow …
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
New combo tackles tough lymphoma in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
Triple attack on lymphoma: freeze, vaccinate, and boost immunity
Disease control CompletedThis study tested a new combination treatment for people with non-Hodgkin lymphoma that had come back. The approach used three steps: first, freezing the tumor to kill cancer cells; second, injecting a personalized vaccine made from the patient's own immune cells; and third, givi…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:50 UTC